InvestSMART

Imugene Limited (ASX: IMU) - Share Price

Current share price for IMU : $0.105 0.03 (22.22%)+

Imugene Limited (IMU), an ASX-listed company, is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. The Company's unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

IMU General Information +

ASX Code IMU
Website http://www.imugene.com
Industry/Sector Biotechnology
Market Cap ($M) 43
IMU Share Price $0.105
Day High $0.110
Day Low $0.100
Last Close $0.135
IMU Share Price Movement $0.03 ( 22.22% )
Prices as at 16:40, 7 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Imugene Limited (IMU) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Imugene Limited (IMU) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Imugene Limited (IMU) price-sensitive announcements

IMU - $11.1 Million Placement Completed to Advance azer-cel
Imugene Limited has successfully completed a $11.1 million placement to advance its lead a
Imugene Limited (IMU)
7 Jul 2026 | 9:49 AM
IMU - Trading Halt
On July 3, 2026, Imugene Limited announced a trading halt for its securities on the Austra
Imugene Limited (IMU)
3 Jul 2026 | 9:31 AM
IMU - New Complete Response in the Concurrent BTKi azer-cel Cohort
Imugene Limited reported an additional complete response in a patient from the concurrent
Imugene Limited (IMU)
1 Jul 2026 | 10:00 AM
IMU - First Complete Response in Concurrent BTKi azer-cel Cohort
Imugene Limited reported a significant milestone in its azer-cel Phase 1b trial, noting th
Imugene Limited (IMU)
30 Jun 2026 | 11:45 AM

Imugene Limited (IMU) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Imugene Limited (IMU)
ORDINARY FULLY PAID
Health Care $44 Notification of cessation of securities - IMU 7 Jul 2026 7:27PM $0.105 $0.105 fallen by 0%
Imugene Limited (IMU)
ORDINARY FULLY PAID
Health Care $44 Change of Director's Interest Notice x5 7 Jul 2026 4:58PM $0.105 $0.105 fallen by 0%
Imugene Limited (IMU)
ORDINARY FULLY PAID
Health Care $44 Imugene Capital Raising Presentation 7 Jul 2026 10:02AM $0.135 $0.105 fallen by 22.22%
Imugene Limited (IMU)
ORDINARY FULLY PAID
Health Care $44 Proposed issue of securities - IMU 7 Jul 2026 9:49AM $0.135 $0.105 fallen by 22.22%
Imugene Limited (IMU)
ORDINARY FULLY PAID
Health Care $44 $11.1 Million Placement Completed to Advance azer-cel 7 Jul 2026 9:49AM $0.135 $0.105 fallen by 22.22%
Imugene Limited (IMU)
ORDINARY FULLY PAID
Health Care $44 Initial Director's Interest Notice - CG & MK 6 Jul 2026 1:45PM $0.135 $0.105 fallen by 22.22%

IMU Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2027F C2 -$9.00 -43.80% 0.00 0.00 0.00% 0.0%
2026F C2 -$16.00 -49.30% 0.00 0.00 0.00% 0.0%
2025A -$69.02 -$31.60 -47.50% 0.00 0.00 0.00% 0.0%

IMU Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2026 F 2027 F 2025 A 2026 F 2027 F 2025 A 2026 F 2027 F
CSL Limited (CSL) $59,495M 0.1108 -0.1224 0.0167 13.3213 15.1792 14.9299 3.59% 2.93% 3.04%
Clinuvel Pharmaceuticals Limited (CUV) $515M 0.0287 0.0000 0.0000 14.2201 0.0000 0.0000 0.49% 0.00% 0.00%
Imugene Limited (IMU) $56M -0.4751 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $2,693M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,898M -1.3893 0.0000 -0.1308 0.0000 320.0737 368.2203 0.00% 0.00% 0.00%

IMU Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.51 0.00
Market 0.28 13.00 1.15 0.59
Sector 0.45 27.70 2.40 1.86

IMU Directors

Name Position Start Date
Ms Leslie (Mi Ok) Chong Chief Executive Officer, Managing Director 28 Mar 2018
Mr Paul Alex Hopper Executive Chairman, Executive Director 31 Oct 2012
Mr Michael John Kotsanis Non-Executive Director 30 Jun 2026
Dr Lesley Russell Non-Executive Director 23 Apr 2019
Dr Charmaine Hilary Gittleson Non-Executive Director 30 Jun 2026
Dr Jakob Dupont Non-Executive Director 7 Sep 2022
Ms Kim Drapkin Non-Executive Director 21 Jun 2023

Imugene Limited (IMU) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
14 May 2026 CHONG, Leslie (Mi Ok) Buy Direct Shares 355,164 $0.103 $36,404.310
14 May 2026 HOPPER, Paul Buy Direct Shares 180,000 $0.104 $18,648.000
11 May 2026 CHONG, Leslie (Mi Ok) Buy Direct Shares 230,285 $0.108 $24,755.638

See all changes in directors' interest & trades for Imugene Limited (IMU) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMU Management

Name Position
Darren Keamy Chief Financial Officer
Darren Keamy Chief Financial Officer,Company Secretary
John Byon Chief Medical Officer
Bradley Glover Chief Operating Officer

IMU Calendar of Events

Date Event
24 February 2027 Report (Interim)
25 August 2026 Report (Annual)
25 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.